Kymab Outlines Positive New Findings for its KY1044 Anti-ICOS Program at the CICON 2019 Annual Meeting
Kymab Outlines Positive New Findings for its KY1044 Anti-ICOS Program at the CICON 2019 Annual Meeting KY1044 increases the ratio of intratumoral cytotoxic-to-regulatory T cells and induces tumor regression Expanding data set continues to provide evidence …